BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with Bristol-Myers and its impact on the firm.

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization agreement. The pact focuses on BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.